MRI for response assessment in metastatic bone disease (original) (raw)
Related papers
Clinical Oncology, 2011
Radiological and nuclear medicine imaging modalities used for assessing bone metastases treatment response include plain and digitalised radiography (XR), skeletal scintigraphy (SS), dual-energy X-ray absorptiometry (DEXA), computed tomography (CT), magnetic resonance imaging (MRI), [ 18 F] fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/CT. Here we discuss the advantages and disadvantages of these assessment modalities as evident through different clinical trials. Additionally, we present the more established response criteria of the International Union Against Cancer and the World Health Organization and compare them with newer MD Anderson criteria. Even though serial XR and SS have been used to assess the therapeutic response for decades, several months are required before changes are evident. Newer techniques, such as MRI or PET, may allow an earlier evaluation of response that may be quantified through monitoring changes in signal intensity and standard uptake value, respectively. Moreover, the application of PET/CT, which can follow both morphological and metabolic changes, has yielded interesting and promising results that give a new insight into the natural history of metastatic bone disease. However, only a few studies have investigated the application of these newer techniques and further clinical trials are needed to corroborate their promising results and establish the most suitable imaging parameters and evaluation time points. Last, but not least, there is an absolute need to adopt uniform response criteria for bone metastases through an international consensus in order to better assess treatment response in terms of accuracy and objectivity.
Therapy monitoring of skeletal metastases with whole-body diffusion MRI
Journal of Magnetic Resonance Imaging, 2014
Current methods of assessing tumor response at skeletal sites with metastatic disease use a combination of imaging tests, serum and urine biochemical markers, and symptoms assessment. These methods do not always enable the positive assessment of therapeutic benefit to be made but instead provide an evaluation of progression, which then guides therapy decisions in the clinic. Functional imaging techniques such as whole-body diffusion magnetic resonance imaging (MRI) when combined with anatomic imaging and other emerging "wet" biomarkers can improve the classification of therapy response in patients with metastatic bone disease. A range of imaging findings can be seen in the clinic depending on the type of therapy and duration of treatment. Successful response to systemic therapy is usually depicted by reductions in signal intensity accompanied by apparent diffusion coefficient (ADC) increases. Rarer patterns of successful treatment include no changes in signal intensity accompanying increases in ADC values (T2 shine-through pattern) or reductions in signal intensity without ADC value changes. Progressive disease results in increases in extent/intensity of disease on high b-value images with variable ADC changes. Diffusion MRI therapy response criteria need to be developed and tested in prospective studies in order to address current, unmet clinical and pharmaceutical needs for reliable measures of tumor response in metastatic bone disease.
Role of whole-body diffusion-weighted MRI in detecting bone metastasis
La Radiologia medica, 2014
The aim of this study was to compare the results of whole-body diffusion-weighted magnetic resonance (DW-MR) imaging with staging based on computed tomography (CT) and nuclear scintigraphy using Tc99m results as the standard of reference. Seventeen patients with known malignant tumours were included in the study. The thorax and the abdomen were imaged using breath-hold diffusion-weighted imaging and T1-weighted imaging sequences in the coronal plane. Location and size of osseous metastases were documented by two experienced radiologists. Whole-body DW-MR imaging findings were compared with results obtained at skeletal scintigraphy and CT bone survey. The mean examination time for whole-body DW-MR imaging was 25.5 min. All bone metastases regardless of the size were identified with whole-body DW-MR imaging; MR imaging depicted more bone metastases than CT. Skeletal scintigraphy depicted osseous metastases in 13 patients (with greater sensitivity to the lower limb), whereas whole-body...
International Congress Series, 2005
Purpose: We assessed the diagnostic value of whole body magnetic resonance (MR) imaging (WB-MRI) using diŠusion-weighted images (DWI) for detecting bone metastasis and compared it with that of skeletal scintigraphy (SS). Materials and Methods: Thirty patients with malignancies (breast cancer, 17 patients; prostate cancer, 9; and one patient each, thyroid cancer, liposarcoma, leiomyosarcoma, and extraskeletal Ewing sarcoma) underwent both WB-MRI and SS to detect bone metastasis. All patients were followed more than 6 months by MR imaging, SS, or computed tomographic (CT) examination. For WB-MRI, patients were placed in feet-ˆrst supine position with table-top extender and quadrature body coil. We acquired DWI (axial plane from lower neck to proximal femur) (single shot short TI inversion-recovery [STIR]: repetition time [TR] 6243/echo time [TE] 59/inversion time [TI] 180 ms; b value: 600 s/mm 2 ; 5-mm slice thickness; 112×112 matrix), T 1-weighted fast spin echo (T 1 WI), and STIR (sagittal plane of total spine images and coronal plane of whole body images) images. Four blinded readers independently and separately interpreted images of combined MR sequences of T 1 WI＋STIR (session 1) and T 1 WI＋STIR＋DWI (session 2). Results: In 10 of 30 patients, we detected a total of 52 metastatic bone lesions; in the other 20, follow-up examinations conˆrmed no metastatic bone lesions. For these 52 lesions, for session 2, the mean sensitivity was 96z and the positive predictive value (PPV) was 98z. Those values were superior to those of session 1 (sensitivity: 88z; PPV: 95z) and those of SS (sensitivity: 96z; PPV: 94z). Conclusion: WB-MRI that included DWI was useful for detecting bone metastasis.
Journal of Radiotherapy, 2014
This study examined the usefulness of diffusion-weighted (DW) Magnetic Resonance Imaging (MRI) in monitoring bone metastases response to radiation therapy in 15 oligometastatic patients. For each metastasis, both mean apparent diffusion coefficient (ADC) changes and high b-value DW metastasis/muscle signal intensity ratio (SIR) variations were evaluated at 30 ± 5 days and 60 ± 7 days after the end of treatment. On baseline DW-MRI, all bone metastases were hyperintense and had signal intensities higher than normal bone marrow on calculated ADC maps. At follow-up evaluations, 4 patterns of response were identified: (I) decreased high b-value DW SIR associated with increased mean ADC (83.3% of cases); (II) increased mean ADC with no change of high b-value DW SIR (10% of cases); (III) decreased both high b-value DW SIR and mean ADC (3.3% of cases); (IV) a reduction in mean ADC associated with an increase in high b-value DW SIR compared to pretreatment values (3.3% of cases). Patterns (I...
Journal of Clinical Orthopaedics and Trauma
Aim: This study aimed to use multiparametric magnetic resonance imaging (MRI) techniques, namely, diffusion-weighted imaging (DWI) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to evaluate bone tumors. Methods: Thirty-three patients with primary untreated bone tumors were assessed utilizing DWI and DCE-MRI. Various parameters like ADC values from DWI and percentage peak signal intensity (%PSI), the maximum slope of increase (MSI), and time to peak signal intensity (TTP) values were assessed in different cases, and the final correlation was drawn with histopathological findings. Result: Parameters of semi-quantitative DCE-MRI, i.e., %PSI, MSI and, TTP, correlated significantly with the histopathological characteristics of the tumor (p values < 0.001). Minimum ADC value in the tumor also showed a strong correlation with the tumor characteristic (p values < 0.001). Also, the correlation between parameters of DWI and DCI-MRI is well correlated with each other. Conclusion: The results of this study provide grounds for the integration of multiparametric pretreatment evaluation of bone tumors. In our study, we not only tried to utilize different parameters of functional MRI in bone tumors as well as re-explored the semi-quantitative analysis of DCE-MRI.
MRI in primary bone tumors: therapeutic implications
European Journal of Radiology, 1991
The accuracy of preoperative MRI in detecting tumor extent has been evaluated in 35 patients with primary bone neoplasms; intra-osseous extent was measured on MR images and compared with macroslides of surgical specimens in 26 cases. An almost completely accurate prediction of tumor size was obtained with the combined employment of Spin-Echo (SE) and Short Inversion Time Inversion Recovery (STIR) sequences in the various tumors, with the exception of two Ewing's sarcomas. Changes in Signal Intensity (SI) and tumor morphology were identified in those cases which had undergone presurgical chemotherapy: the reduction in SI and in tumor size or the appearance of a more homogeneous signal was correlated with a positive response to cytotoxic therapy. MR imaging fully satisfies surgeon's preoperative requirements in the assessment of therapy-responding neoplasms as well as in local tumor staging in all types of neoplasms, with the exception of Ewing's sarcoma.